Stokes G S, Raftos J, Lewis R G, Mitchell A S, Jeremy D, Frost G W, Thornell I R
J Cardiovasc Pharmacol. 1982;4 Suppl 1:S172-5. doi: 10.1097/00005344-198200041-00034.
Combined use of prazosin and beta-blockers in a hypertension clinic over a 3-year period was surveyed by means of a computerized record system. Of the 1,250 patients in the clinic, 171 (14%) had been treated with this combination for periods averaging 17 months. Prazosin was administered with a beta 1-selective beta-blocker in 94 cases and with a beta 1 + beta 2-blocker in 100 cases; 23 patients had received treatment with both combinations. Diuretics were given in 86% of cases and other antihypertensive drugs in 19%. The population treated had a high incidence of severe hypertension, with initial diastolic pressure greater than 120 mm Hg in 38% and between 100 and 120 mm Hg in 50%. The percentage of patients with diastolic pressure less than 100 mm Hg was 12% initially and 79% at the end of the treatment period. Side effects necessitated withdrawal of therapy in 35 cases. These were referable in 19 cases to prazosin and in 16 to beta-blockers. Prazosin was found to be more effective in lowering blood pressure in combination with beta 1-blockers than with beta 1 + beta 2-blockers, although there were fewer severe side effects with beta 1-blockers.
通过计算机记录系统对一家高血压诊所三年期间哌唑嗪与β受体阻滞剂的联合使用情况进行了调查。在该诊所的1250名患者中,有171名(14%)接受了这种联合治疗,平均治疗时间为17个月。94例患者使用哌唑嗪与β1选择性β受体阻滞剂联合治疗,100例患者使用哌唑嗪与β1+β2受体阻滞剂联合治疗;23例患者接受了两种联合治疗。86%的病例使用了利尿剂,19%的病例使用了其他抗高血压药物。接受治疗的人群中重度高血压发病率较高,初始舒张压大于120mmHg的占38%,在100至120mmHg之间的占50%。初始舒张压低于100mmHg的患者比例为12%,治疗期末为79%。35例患者因副作用而停药。其中19例与哌唑嗪有关,16例与β受体阻滞剂有关。虽然使用β1受体阻滞剂时严重副作用较少,但发现哌唑嗪与β1受体阻滞剂联合使用比与β1+β2受体阻滞剂联合使用更有效地降低血压。